Mumps
68
1
2
55
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
27 trials with published results (40%)
Research Maturity
55 completed trials (81% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.4%
3 terminated out of 68 trials
94.8%
+8.3% vs benchmark
68%
46 trials in Phase 3/4
49%
27 of 55 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 55 completed trials
Clinical Trials (68)
Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Measles, Mumps, and Rubella (MMR) Immunity in College Students
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds